Your browser doesn't support javascript.
Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo.
Schäfer, Alexandra; Muecksch, Frauke; Lorenzi, Julio C C; Leist, Sarah R; Cipolla, Melissa; Bournazos, Stylianos; Schmidt, Fabian; Gazumyan, Anna; Baric, Ralph S; Robbiani, Davide F; Hatziioannou, Theodora; Ravetch, Jeffrey V; Bieniasz, Paul D; Nussenzweig, Michel C; Sheahan, Timothy P.
  • Schäfer A; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Muecksch F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, 10065.
  • Lorenzi JCC; Laboratory of Molecular Immunology, Rockefeller University, New York, NY 10065.
  • Leist SR; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Cipolla M; Laboratory of Molecular Immunology, Rockefeller University, New York, NY 10065.
  • Bournazos S; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, 10065.
  • Schmidt F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, 10065.
  • Gazumyan A; Laboratory of Molecular Immunology, Rockefeller University, New York, NY 10065.
  • Baric RS; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.
  • Robbiani DF; Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Hatziioannou T; Laboratory of Retrovirology, The Rockefeller University, New York, NY, 10065.
  • Ravetch JV; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Bieniasz PD; Laboratory of Retrovirology, The Rockefeller University, New York, NY, 10065.
  • Nussenzweig MC; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY, 10065.
  • Sheahan TP; Laboratory of Retrovirology, The Rockefeller University, New York, NY, 10065.
bioRxiv ; 2020 Sep 15.
Article in English | MEDLINE | ID: covidwho-807036
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a mouse adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). In vitro antibody neutralization potency did not uniformly correlate with in vivo activity, and some hu-mAbs were more potent in combination in vivo . Analysis of antibody Fc regions revealed that binding to activating Fc receptors is essential for optimal protection against SARS-CoV-2 MA. The data indicate that hu-mAb protective activity is dependent on intact effector function and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines Language: English Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies Topics: Vaccines Language: English Year: 2020 Document Type: Article